Actively Recruiting
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Led by Dana-Farber Cancer Institute · Updated on 2026-02-19
30
Participants Needed
1
Research Sites
369 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).
CONDITIONS
Official Title
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed patients with stages III-IV ovarian or endometrial cancer
- Receiving first-line carboplatin and paclitaxel chemotherapy after surgery
- 18 years or older
- Physician's clearance to participate in moderate-vigorous intensity exercise
- Able to read, write, and understand English
- Willing and able to sign an informed consent form
- Willing to undergo two venous blood draws for the study
You will not qualify if you...
- Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions as determined by the treating oncologist
- Uncontrolled intercurrent illness as determined by the treating oncologist
- Psychiatric illness or social situations limiting study compliance as determined by the treating oncologist
- Prior chemotherapy for cancer treatment (e.g., taxanes for breast cancer)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
C
Christina Dieli-Conwright, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here